Ophthalmology and therapy · 2026
Treatment Persistence with Combination Eye Drops for Glaucoma: A Longitudinal Analysis Using Japanese Medical Claims Data.
СтатьяНазвание и аннотация: Перевод пока не подготовлен
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Kashiwagi Kenji, Matsukawa Miyuki, Toda Rikiya, Okamoto Kana, Michikami Daisaku
Аннотация
INTRODUCTION: Glaucoma is a chronic progressive disease and the leading cause of blindness, particularly among older individuals. Treatment persistence with intraocular pressure (IOP)-lowering therapy is essential to avoid visual impairment, although data on persistence with combination eye-drop therapy are lacking. The objective of this study was to evaluate treatment persistence with combination eye-drop therapy in Japanese patients with glaucoma or ocular hypertension.
METHODS: This longitudinal cohort study analysed anonymised insurance claims data from the DeSC database. Adults (≥ 18 years) with glaucoma or ocular hypertension who initiated IOP-lowering therapy within the same month as their diagnosis between June 2020 and May 2023 were included. The primary outcomes were: (1) treatment persistence among patients who initiated carteolol/latanoprost-based combination therapy (research question [RQ] 1); (2) persistence according to the number of bottles and active IOP-lowering ingredients (RQ2); (3) persistence according to the number of bottles of eye drops (RQ3); and (4) persistence according to concomitant use of different IOP-lowering drugs (RQ6).
RESULTS: Among patients who initiated carteolol/latanoprost (RQ1 cohort; n = 28,560), the 360-day persistence rates were highest with concomitant brimonidine/brinzolamide (23.0%) and lowest with ripasudil (16.5%). The median duration of persistence was longer with concomitant brimonidine or brimonidine/brinzolamide versus concomitant brinzolamide, ripasudil or dorzolamide (148 vs 130, 120 and 117 days, respectively). Persistence also increased with increasing number of active IOP-lowering ingredients (RQ2 cohort; two-bottles, n = 160,481; three-bottles, n = 48,994) but declined with increasing number of bottles of eye drops (RQ3 cohort; n = 188,676). Combination therapy with a β-blocker plus a prostaglandin F2α receptor agonist showed a trend towards having the longest persistence duration, while β-blocker plus carbonic anhydrase inhibitor regimens showed a trend towards the shortest duration (RQ6).
CONCLUSION: These findings suggest that treatment persistence with combination eye-drop therapy in Japanese patients with glaucoma or ocular hypertension may differ depending on the IOP-lowering regimen.
METHODS: This longitudinal cohort study analysed anonymised insurance claims data from the DeSC database. Adults (≥ 18 years) with glaucoma or ocular hypertension who initiated IOP-lowering therapy within the same month as their diagnosis between June 2020 and May 2023 were included. The primary outcomes were: (1) treatment persistence among patients who initiated carteolol/latanoprost-based combination therapy (research question [RQ] 1); (2) persistence according to the number of bottles and active IOP-lowering ingredients (RQ2); (3) persistence according to the number of bottles of eye drops (RQ3); and (4) persistence according to concomitant use of different IOP-lowering drugs (RQ6).
RESULTS: Among patients who initiated carteolol/latanoprost (RQ1 cohort; n = 28,560), the 360-day persistence rates were highest with concomitant brimonidine/brinzolamide (23.0%) and lowest with ripasudil (16.5%). The median duration of persistence was longer with concomitant brimonidine or brimonidine/brinzolamide versus concomitant brinzolamide, ripasudil or dorzolamide (148 vs 130, 120 and 117 days, respectively). Persistence also increased with increasing number of active IOP-lowering ingredients (RQ2 cohort; two-bottles, n = 160,481; three-bottles, n = 48,994) but declined with increasing number of bottles of eye drops (RQ3 cohort; n = 188,676). Combination therapy with a β-blocker plus a prostaglandin F2α receptor agonist showed a trend towards having the longest persistence duration, while β-blocker plus carbonic anhydrase inhibitor regimens showed a trend towards the shortest duration (RQ6).
CONCLUSION: These findings suggest that treatment persistence with combination eye-drop therapy in Japanese patients with glaucoma or ocular hypertension may differ depending on the IOP-lowering regimen.